The risk of mortality, stroke, heart attack or bleeding is not increased in patients treated with Lucentis when compared with those treated with either photodynamic therapy (PDT) or Macugen.
The use of a non-selective anti-VEGF agent such as Lucentis had led to concerns about the potential systemic impact upon vascular health and recovery. This was less of a concern for selective agents, such as Macugen, or PDT. However, a study in Archives of Ophthalmology (2010128(10):1273-1279) followed over 145,000 AMD patients variously treated and found no such pattern.
Indeed, the study shows no significant relationship between any observed treatments and bleeding events or stroke.
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here